Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 7/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.34 |
| ▸ | ACP1 | P24666 | 1/20 | 0.34 |
| ▸ | CDC25B | P30305 | 1/20 | 0.34 |
| ▸ | CRHBP | P24387 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.34 |
| ▸ | AGTR1 | P30556 | 2/20 | 0.32 |
| ▸ | LTB4R2 | Q9NPC1 | 2/20 | 0.32 |
| ▸ | CNR1 | P21554 | 1/20 | 0.32 |
| ▸ | CNR2 | P34972 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1841249 | 0.88 | ALDH1A1 (0.36) | ACHEALDH1A1CYP3A4 | |
| SCHEMBL9526661 | 0.88 | ALDH1A1 (0.38) | ALDH1A1CYP3A4 | |
| SCHEMBL19790062 | 0.81 | ALDH1A1 (0.38) | ALDH1A1CYP3A4 | |
| SCHEMBL1837556 | 0.78 | SMN1; SMN2 (0.36) | ALDH1A1CYP3A4HTTNPSR1 | |
| SCHEMBL7220404 | 0.74 | CDC25A (0.33) | ACHEALDH1A1CDC25B | |
| SCHEMBL19790037 | 0.72 | ALDH1A1 (0.37) | ALDH1A1CYP3A4 | |
| SCHEMBL1838114 | 0.72 | ALDH1A1 (0.39) | ALDH1A1CYP3A4 | |
| SCHEMBL9863514 | 0.71 | ALDH1A1 (0.36) | ALDH1A1CYP3A4 | |
| SCHEMBL2494925 | 0.70 | CDC25B (0.33) | ALDH1A1PTPN1ACP1CDC25B | |
| SCHEMBL1841614 | 0.69 | KCNJ1 (0.33) | ALDH1A1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2007052301-A2 | PROCESS FOR THE PREPARATION OF IRBESARTAN | ALEMBIC LIMITED (IN) | 2007-05-10 | — | — | WO | claimed |
| EP-1919469-B1 | PROCESS FOR PREPARING AN ANGIOTENSIN II RECEPTOR ANTAGONIST | FARMAPROJECTS S A (ES) | 2011-02-16 | — | — | EP | disclosed |
| EP-1919469-B1 | PROCESS FOR PREPARING AN ANGIOTENSIN II RECEPTOR ANTAGONIST | FARMAPROJECTS S A (ES) | 2011-02-16 | — | — | EP | disclosed |
| EP-2194050-A1 | A new process for the preparation of irbesartan | KRKA, tovarna zdravil, d.d., Novo mesto (SI) | 2010-06-09 | — | — | EP | disclosed |
| US-20080281097-A1 | Process for Preparing an Angiotensin II Receptor Antagonist | FARMAPROJECTS, S. A. (ES) | 2008-11-13 | — | — | US | disclosed |
| US-20080281097-A1 | Process for Preparing an Angiotensin II Receptor Antagonist | FARMAPROJECTS, S. A. (ES) | 2008-11-13 | — | — | US | disclosed |
| US-20080281097-A1 | Process for Preparing an Angiotensin II Receptor Antagonist | FARMAPROJECTS, S. A. (ES) | 2008-11-13 | — | — | US | disclosed |
| EP-1919469-A2 | PROCESS FOR PREPARING AN ANGIOTENSIN II RECEPTOR ANTAGONIST | Farmaprojects, S.A. (ES) | 2008-05-14 | — | — | EP | disclosed |
| WO-2007052301-A3 | PROCESS FOR THE PREPARATION OF IRBESARTAN | ALEMBIC LTD (IN) | 2007-07-12 | — | — | WO | disclosed |
| WO-2007052301-A2 | PROCESS FOR THE PREPARATION OF IRBESARTAN | ALEMBIC LIMITED (IN) | 2007-05-10 | — | — | WO | disclosed |
| WO-2007052301-A2 | PROCESS FOR THE PREPARATION OF IRBESARTAN | ALEMBIC LIMITED (IN) | 2007-05-10 | — | — | WO | disclosed |
| WO-2007017469-A2 | PROCESS FOR PREPARING AN ANGIOTENSIN II RECEPTOR ANTAGONIST | FARMAPROJECTS, S. A. (ES) | 2007-02-15 | — | — | WO | disclosed |
| WO-2007017469-A2 | PROCESS FOR PREPARING AN ANGIOTENSIN II RECEPTOR ANTAGONIST | FARMAPROJECTS, S. A. (ES) | 2007-02-15 | — | — | WO | disclosed |
| EP-1749828-A1 | Process for preparing an angiotensin II receptor antagonist | FARMAPROJECTS S.L. (ES) | 2007-02-07 | — | — | EP | disclosed |
| EP-1749828-A1 | Process for preparing an angiotensin II receptor antagonist | FARMAPROJECTS S.L. (ES) | 2007-02-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080281097-A1 | Process for Preparing an Angiotensin II Receptor Antagonist | AGTR2, AGTR1, REN | ACHE 4719/4885ALDH1A1 1267/4885CYP3A4 662/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.